Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of NST-4016 in Patients With Nonalcoholic Steatohepatitis (NASH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Dec 2023
Price :
$35
*
At a glance
- Drugs Icosabutate (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms ICONA; ICONA NASH
- Sponsors NorthSea Therapeutics
- 14 Nov 2023 Results assessing the efficacy of Icosabutate in NASH/MASH patients with F1-F3 fibrosis, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
- 10 Nov 2023 According to Northsea Therapeutics media release, primary endpoint (percentage of patients with resolution of NASH, defined as disappearance of ballooning (score = 0) with lobular inflammation score 0 or 1, with no worsening of fibrosis.) has not been met.
- 10 Nov 2023 According to Northsea Therapeutics media release, data from the study will be presented as an oral late-breaker at the AASLD Liver Meeting in Boston on November 13, 2023.